Cardiome Announces Agreement With Tzamal Medical to Sell Brinavess In Israel
Cardiome Pharma Corp. (NASDAQ: CRME) today announced that its subsidiary, Cardiome Development AG,
has entered into an agreement with Tzamal Medical Ltd., to sell and
distribute BRINAVESS™ (vernakalant intravenous) exclusively in Israel.
Under the terms of the agreement, Tzamal Medical has agreed to specific
annual commercial goals for BRINAVESS. Financial details of the
agreement have not been disclosed.
"This agreement with Tzamal Medical reaffirms Cardiome's commitment to
continue making BRINAVESS available worldwide, including markets
outside of Europe," said Karim Lalji, Cardiome's Chief Commercial
Officer. "We are pleased to have partnered with an industry leader and
look forward to leveraging Tzamal Medical's expertise to commercialize
BRINAVESS in the Israeli market."